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Aims: A Krukenberg tumor (KT) is an uncommon type of ovarian cancer (OC) with poor prognosis. We
sought to identify prognostic factors for KT originating from primary gastrointestinal (GI) tumors.
Methods: Forty-four patients with KT were assessed with follow-up. The primary endpoint was overall
survival (OS) after ﬁrst gynecological or GI surgery.
Results: The use of postoperative chemotherapy, unilaterally involved ovarian mass, resection of primary
tumors, absence of metastatic residuals, and diagnosis of GI tumors synchronously with or after gyne-
cological surgery were identiﬁed to be prognostically favorable. For OS after the ﬁrst cancer-related
surgery, only the resection of primary tumor and absence of metastatic residuals were found to be
favorable prognostic factors. The use of postoperative chemotherapy correlated with intraoperative
intraperitoneal use of chemotherapy, but not with patients’ clinicopathological characteristics, which
were not found to be associated with any factors.
Conclusion: The prognostic value of a factor depends on how survival is deﬁned. Optimal cytoreductive
surgery followed by aggressive chemotherapy may improve survival in KT patients. KT patients with
unilaterally involved ovarian mass, resected primary tumors, and the absence of metastatic lesion re-
siduals also seem to have a more favorable prognosis.
Copyright  2013, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
A Krukenberg tumor (KT) is an uncommon type of metastatic
ovarian cancer with poor prognosis and can account for 30e40% of
metastatic cancers to the ovaries.1e3 There is a lack of consensus on
the optimal treatment modality for KT, and the role of surgery and
chemotherapy in improving patient survival still remains contro-
versial.4 No universally accepted prognostic factors for KT are
currently available.5
Owing mainly to its poor prognosis, various attempts have been
made to identify prognostic factors for KT. These attempts are often
tenuous because of the rarity of KT. Kim et al6 found that the
absence of residual disease after treatment and limited disease
extent are favorable prognostic factors. Cheong et al4,7 found that
metastasectomy is associated with improved survival. McCormick
et al8 reported that metastasectomy is a favorable prognostic factor
for survival. Very recently, Jiang et al9 reported that KT patientsGynecology Hospital, Fudan
.
ork.
ia-PaciﬁcAssociationforGynecologicEfrom colorectal cancer experience a better prognosis than those
from gastric cancer and beneﬁt more from metastasectomy.
For early-stage ovarian cancer and in patients with well or
moderately differentiated early-stage ovarian cancer conﬁned to
the pelvis, surgical treatment alone may be curative. However, the
variable 5-year survival rates prompted for all kinds of adjuvant
treatment, mostly chemotherapy.10 For patients with advanced
primary ovarian cancers, surgical treatment combined with
platinum-based adjuvant chemotherapy may improve overall and
recurrence-free survival.11 For KT, postoperative adjuvant chemo-
therapy conceivably may be of value in prolonging overall survival
in patients with KT. Unfortunately, the prognostic value of post-
operative chemotherapy in KT has not been fully investigated, due,
again, to the rarity of the disease.
In this study, we sought to identify prognostic factors for KT
among 44 women with surgically conﬁrmed metastatic ovarian
cancer originating from the gastrointestinal (GI) tract via multi-
variate analysis. In addition, we sought to identify the interrela-
tionship, if any, among various potential prognostic factors. Unlike
many published studies on KT which focused exclusively on pa-
tients who had undergone primary resection of GI tumors and
metachronously developed ovarian metastasis, we attempted to
identify prognostic factors for KT based on gynecological patients.ndoscopyandMinimally InvasiveTherapy.PublishedbyElsevierTaiwanLLC.All rightsreserved.
Table 1
Clinicopathological characteristics of 44 patients with Krukenberg tumor (KT) and
statistical signiﬁcance of their impact on overall survival.
Variable Distribution p* p*
Age at diagnosis (y), mean  SD 47.9  11.6
Range 20e75 0.57a 0.93a
Median 47.5
Menopausal status, n (%)
Premenopausal 21 (47.7) 0.78 0.74
Menopausal 23 (52.3)
Laterality
Unilateral 19 0.13 0.10
Bilateral 23
Unknown 2
Size of ovarian tumor





pelvic ascites, n (%)
No 12 (27.3) 0.44 0.11
Yes 32 (72.7)
Sequence of tumor discovery, n (%)
GI tract ﬁrst, ovarian second 13 (29.6) 0.61 0.0005
Synchronously 21 (47.7)
Ovarian cancer ﬁrst, then GI tract 10 (22.7)
Type of surgery
TAH þ BSO  omentectomy 36 NAb NAb
BSO only 3




Platinum-based intraoperative intraperitoneal chemotherapy, n (%)
No 25 (56.8) 0.58 0.53
Yes 19 (43.2)
Postoperative adjuvant chemotherapy, n (%)
None 12 (27.3) 6.3  105 0.24
Nonaggressive 15 (34.1)
Aggressive 17 (38.6)
Presence of residuals of metastatic lesions, n (%)
No 23 (52.3) 0.15 0.005
Yes 21 (47.7)
Resection of primary GI tumors, n (%)
Yes 17 (38.6) 0.54 3.6  105
No 27 (61.4)
Serum CA-125 level (U/mL)
Mean  SD 136.5  171.2 0.51a 0.02a
Range 0.1e747
Median (number of missing
values: n ¼ 11)
44.0
*The ﬁrst column of p values is for overall survival starting from gynecological
surgery, whereas the second column is for overall survival starting from the ﬁrst
cancer-related surgery.
a Based on univariate Cox regression analysis.
b Analysis not performed owing to very small sample sizes in some subgroups.
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after the ﬁrst cancer-related surgery and compared them with
those for overall survival after gynecological surgery.
Materials and methods
Patients
In a 12-year period spanning from 1995 to 2007, 1416 patients
were surgically diagnosed with ovarian cancer at Shanghai Ob-
stetrics and Gynecology Hospital, Fudan University. Among them,
45 cases were conﬁrmed to be KT, accounting for 3.2% of all ovarian
cancers. For these 45 patients, we retrieved their clinicopatholog-
ical information through medical charts and histology review with
assistance of an experienced gynecological pathologist. With one
exception in which we could not track down the patient, we suc-
cessfully followed up all these patients, retrieving information on
date of death, results of pelvic and sonographic examinations, CA-
125, and results from computer tomography (CT)/magnetic reso-
nance imaging (MRI) scans, when available.
This research was approved by the Institutional Ethics Review
Board of Shanghai Obstetrics and Gynecology Hospital.
Statistical analysis
The comparison of distributions of continuous variables be-
tween two or among three or more groups was made using the
Wilcoxon rank test and KruskaleWallis test, respectively. Fisher’s
exact test was used to detect whether there is any relation between
two categorical variables. Pearson’s correlation coefﬁcient was used
when evaluating correlations between two variables when both
variables are continuous. When at least one variable is ordinal,
Spearman’s rank correlation coefﬁcient was used instead.
The overall survival was represented in months, which was
deﬁned as the interval between the date of gynecological surgery
and the date of death or of the last follow-up when alive. Overall
survival curves were estimated by the KaplaneMeier method, and
difference in survival was evaluated using the log-rank test. For
multivariable analysis, the Cox regression model was used, along
with the stepwise backward elimination procedure. The potential
covariates of interest included age at diagnosis, menopausal status,
timing of operation, laterality of ovarian mass, mass volume,
presence of ascites, intraoperative intraperitoneal chemotherapy,
and use of aggressive adjuvant chemotherapy postoperatively. A p
value of 0.05 or less was regarded as statistically signiﬁcant. All
computations were made with R 2.12.212 (www.r-project.org).
Results
The clinicopathological characteristics of the 44 patients are
listed in Table 1. Among them, 39 (88.6%) died from cancer com-
plications. The age of menopausal patients ranged from 44 years
old to 75 years old, with a median of 56 years old. In the premen-
opausal patients, their ages ranged from 20 years old to 52 years
old, with a median of 40 years. The median (range) age of patients
who had GI cancer diagnosed prior to diagnosis of metastatic
ovarian cancer was 45 (33e60) years, as compared with 51 (20e75)
years and 45 (31e70) years, respectively, in patients who had
synchronous diagnosis of GI and ovarian cancers and after diag-
nosis of ovarian cancer. Although the age in the ﬁrst group was
slightly younger, the difference did not reach statistical signiﬁcance
(p ¼ 0.27).
All patients admitted into the hospital complained of abdominal
distention, abdominal pain, pelvic mass, and, in a few cases, post-
menopausal vaginal bleeding. At the time of operation, 13 patients(29.6%) had already had a curative resection of GI tumors previ-
ously, 21 (47.7%) were found to have primary GI tumors synchro-
nously during gynecological surgery, and the remaining 10 (22.7%)
were suspected to have primary GI tumors during surgery, and later
conﬁrmed by either endoscopy or CT/MRI examination after sur-
gery. The sites of the GI tract were stomach (n ¼ 42, 95.5%) and
intestines (n ¼ 2, 4.5%) in all patients.
During the operation, 19 cases (43.2%) and 23 cases (52.3%) were
found to have unilateral and bilateral ovarianmass, respectively, and
two (4.6%) were found to have microscopic bilateral metastatic le-
sions (Table 1). Of all patients, 24 cases (54.5%) were found to have
metastatic lesions in both the abdomen and the pelvis. For patients
with ovarian mass, their sizes were measured (Table 1). Thirty-two
cases (72.7%) had moderate to massive pelvic ascites.
All 44 patients underwent gynecological surgical treatment.
Ascites were collected during surgery for cytological examination.













Post-operative chemotherapy and overall survival












Fig. 1. Postoperative adjuvant chemotherapy and overall survival. Aggressive chemo-
therapy is deﬁned in the text.
Table 2
Parameter estimates of the Cox regression model on factors associated with overall
survival after gynecological surgery.
Covariate Estimate Standard
error
Hazard ratio (95% CI) p
Chemotherapy 1.748 0.174 0.174 (0.063, 0.479) 0.001
Bilaterality of ovarian mass 0.928 0.418 2.529 (1.114, 5.740) 0.027
Failure to resect primary
GI tumors
1.899 0.848 6.682 (1.267, 35.230) 0.025
Presence of residual
metastatic lesions
1.066 0.382 2.905 (1.374, 6.142) 0.005
GI cancer diagnosed later
or synchronously
2.704 0.926 0.067 (0.011, 0.411) 0.003
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operative pathological examinations identiﬁed metastatic ovarian
adenocarcinoma with KT-characteristic mucin-ﬁlled signet ring
cells in all patients.13 Among the 13 patients who had GI tumor
surgery previously, 11 (84.6%) had a total abdominal hysterectomy
and bilateral salpingo-oophorectomy (TAH þ BSO) with or without
omentectomy, 1 (7.7%) had BSO only, and the remaining 1 (7.7%)
received explorative laparotomy only because of unresectable le-
sions. All patients received postoperative chemotherapy with 5-
ﬂuorouracil plus cisplatin. In the remaining 31 patients who had
primary GI cancer diagnosed synchronously with ovarian cancer or
after, two (6.5%) had BSO only, and 29 (93.5%) had TAH þ BSO with
or without omentectomy. In these 31 patients, four cases (12.9%)
also received en bloc resection of primary GI tumors but the
remaining 27 cases (87.1%) did not, either because of unresectable
GI lesions or because the patients and their families declined
further treatment.
Of all patients, 40 cases (90.9%) received TAH þ BSO with or
without omentectomy, three (6.8%) received BSO only, and in one
case an explorative laparotomy was performed because of unre-
sectable lesions. Twenty-one (47.7%) cases had residues of meta-
static lesions and the remaining 23 (52.3%) did not. Nineteen
(43.2%) patients received platinum-based intraoperative intraper-
itoneal chemotherapy and the other 25 (56.82%) did not.
After surgery, all patients were evaluated once a month in the
ﬁrst 6 months and then once in 3 months, and then twice a year.
Thirty-two patients (72.7%) received adjuvant chemotherapy
postoperatively and the remaining 12 (27.3%) received none.
Chemotherapy options included mostly 5-ﬂuorouracil plus
cisplatin or paclitaxel plus carboplatin. Among the 32 patients who
received postoperative chemotherapy, 17 (38.6%) received aggres-
sive chemotherapy, deﬁned here as receiving four to six consecu-
tive cycles of chemotherapy, and the other 15 patients (34.1%) thus
received nonaggressive chemotherapy (i.e., <4 cycles).
The interval between surgical diagnosis of a primary carcinoma
in the GI tract and subsequent discovery of ovarian involvement for
the 13 patients ranged from 4months to 96months or 8 years, with
a median of 2 years and a mean (SD) of 34.1 (28.2) months, in
agreement with the literature.14
Survival and potential prognostic factors
The overall median survival period was 9.8 months [95% conﬁ-
dence interval (CI) ¼ 7.5e15.4 months], with 1- and 2-year survival
rates of 37.9% and 10.2%, respectively. Survival rate beyond 35.6
months was unavailable due to censoring.
Univariate analysis suggested that postoperative chemotherapy
is the only factor that is signiﬁcantly associated with survival
(Table 1, Fig. 1). The median survival time was 4.7 months, 7.5
months, and 20.4 months, respectively, for patients who received
no, nonaggressive, and aggressive chemotherapy. For patients who
had GI tumor diagnosed before, during, or after gynecological
surgery, their median survival was 13.2 [95% CI ¼ 9.2eNA (not
available)], 10.1 (95% CI ¼ 4.7e23.0), and 9.1 (95% CI ¼ 4.9eNA)
months, respectively. The difference, however, did not reach sta-
tistical signiﬁcance.
Cox regression analysis identiﬁed bilateral ovarian mass, post-
operative chemotherapy, whether primary tumor was diagnosed
before metastatic ovarian cancer surgery or not, the presence of
residuals of metastatic lesions, and resection of primary GI tumors
or not as ﬁve prognostic variables (Table 2). Marginally, the median
survival of unilateral and bilateral presence of ovarian carcinoma in
these patients was 11.2 (95% CI ¼ 10.1eNA) months and 6.2 (95%
CI ¼ 4.0e18.3) months, respectively. That is, KT patients with uni-
lateral ovarian mass had approximately 80% longer median survivalthan those with bilateral ovarian mass. For patients who had GI
cancer diagnosed ﬁrst, the median survival was 9.1 months, as
compared with 10.9 months in patients who had GI cancer diag-
nosed during or after gynecological surgery. The difference in me-
dian survival between patients who did not receive resection of
primary GI tumors and who did was very small (10.1 vs. 9.8
months). By contrast, the difference in median survival between
patients who had residuals of metastatic lesions and who did not
appeared to be considerable: 9.2 vs. 13.2 months.
Indeed, the Cox model concluded that, with everything else
being equal, the use of postoperative chemotherapy reduced the
risk of death from cancer by over 80%, and bilaterally involved
ovarian mass doubled the risk of death as compared with unilateral
ovarian cancer (Table 2). The failure to resect primary GI tumors
increased the risk of death by almost 7-fold, whereas the presence
of residuals of metastatic lesions increased the risk by nearly 3-fold.
Among all patients with KT, having their primary GI tumor diag-
nosed ﬁrst increased the risk of death by 14.3-fold as compared
with those with their primary GI tumor diagnosed synchronously
with or after diagnosis of the ovarian metastasis.
There was an indication that the use of aggressive chemo-
therapy was more effective in prolonging life, and the Cox regres-
sion model using two dummy variables suggested that this was the
case. The use of both aggressive and nonaggressive chemotherapy
was signiﬁcant (p ¼ 2.4  104, and p ¼ 0.030).













Resection of primary GI tumors and overall survival 







Fig. 3. Timing of diagnosis and overall survival since the ﬁrst cancer-related surgery.
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From a patient’s perspective, it is perhaps of equal interest to
focus on survival after the ﬁrst cancer-related surgery, regardless if
it was GI surgery or gynecological surgery. Therefore, we added the
time interval between the two surgeries for the 13 patients who
had GI surgery previously and re-did the analysis.
We found that 1-, 2-, 3-, 5-, and 8-year overall survival rates
were 55.4%, 29.1%, 17.8%, 12.2%, and 0.8%, respectively, which were
in broad agreement with the literature.9 The median survival was
15.5 (95% CI¼ 10.1e23.0) months. Although survival rates appeared
to be increased substantially as compared with overall survival
after gynecological surgery, the median survival only increased by
approximately 50%, or around 6 months.
In addition, we found that sequence of surgery, presence or
absence of residuals of metastatic lesions, resection of primary GI
tumors, and CA-125 are signiﬁcantly associated with overall sur-
vival after the ﬁrst cancer-related surgery (Table 1). In particular,
patients with residuals of metastatic lesions had a less favorable
survival than those without (p ¼ 0.005, Table 1, Fig. 2). We also
found that the failure to resect primary GI tumors was associated
with worse overall survival (p ¼ 3.6  105, Fig. 3).
Cox regression analysis identiﬁed the presence of residuals of
metastatic lesions and the failure to resect primary GI tumors or not
as two prognostic variables. It is interesting to note that three fac-
tors, that is, chemotherapy after gynecological surgery, sequence of
diagnosis, bilaterality of ovarian mass, that were signiﬁcantly asso-
ciatedwith overall survival after gynecological surgery are no longer
signiﬁcant when overall survival after the ﬁrst-cancer related sur-
gery is considered. However, the resection of primary tumors and
the absence of residual metastatic lesions still remain to be the two
main prognostic factors, suggesting that these two factors are
prognostically important for overall survival not only after the ﬁrst-
cancer related surgery but also after gynecological surgery.
Discussion
In this study, we found that the use of postoperative chemo-
therapy is a favorable prognostic factor for survival in patients













Residuals of metastatic lesions and overall survival 







Fig. 2. Presence or absence of residuals of metastatic lesions and overall survival since
the ﬁrst cancer-related surgery.found that bilateral ovarian mass, failure to resect primary GI tu-
mors, presence of residuals of metastatic lesions, and having GI
cancer diagnosed prior to metastatic ovarian cancer diagnosis are
risk factors for overall survival after gynecological surgery. Inter-
estingly, for overall survival after the ﬁrst cancer-related surgery,
failure to resect primary GI tumors and the presence of residuals
of metastatic lesions are the only two risk factors that are asso-
ciated with less favorable survival. Moreover, we found that the
use of postoperative chemotherapy is strongly correlated with
intraoperative use of chemotherapy, but not with patients’ clini-
copathological characteristics, such as presence of ascites, later-
ality of ovarian mass, presence of metastatic lesion residuals and
so on.
Although some previously published reports have addressed the
prognostic value of chemotherapy in KT, these studies are limited
by focusing only on patients who had undergone primary resection
of GI tumors and metachronously developed ovarian metastasis,
which concluded that postoperative chemotherapy could not yield
improved survival.15,16 By contrast, our study focused mostly on KT
patients presented to us initially with gynecological complaints.
The main ﬁnding of our study indicates that postoperative
chemotherapy is signiﬁcantly associated with longer survival of KT
patients, especially aggressive chemotherapy. The median survival
in patients receiving aggressive, nonaggressive, and no chemo-
therapy was 20.4, 7.5, and 4.7 months, respectively. In other words,
patients who received aggressive chemotherapy had over four
times longer median survival than those who did not, and patients
who received nonaggressive chemotherapy had 1.5 times longer
median survival. The patients who received aggressive therapy had
over twice as long as those who received nonaggressive therapy.
As KT is a metastatic ovarian cancer with the potential to spread
to all other organs, postoperative intravenous chemotherapy could
presumably reduce or eliminate malignant cells or inhibit their
growth under certain dosage. Our ﬁndings are in agreement with
previous reports on treating advanced ovarian cancers17 and sug-
gest that chemotherapy, especially aggressive chemotherapy, after
resection of metastatic ovarian tumors as part of the treatment
modality for KT is beneﬁcial for survival. This means that optimal
cytoreductive surgery followed by aggressive chemotherapy may
improve survival in patients with KT.
W. Lu et al. / Gynecology and Minimally Invasive Therapy 2 (2013) 52e5656We found in our study that patients with KT who were diag-
nosed with metastatic ovarian cancer prior to or synchronously
with metastatic GI tumor diagnosis had a longer survival rate. It is
possible that patients who had ovarian cancer diagnosis made after
the primary GI tumor may signal a more metastatic and thus more
aggressive tumor, and hence represent more advanced KT, whereas
those made before could be less advanced. Therefore, time
sequence is thus a proxy for invasiveness of the primary tumor and
thus for prognosis. In the same vein, the presence of bilateral
ovarian masses also signals the severity of KT and thus is of prog-
nostic value.
However, the effect of surgery sequence disappears if survival
after the ﬁrst cancer-related surgery is considered. This is because
of an intrinsic bias in favor of those who had primary GI tumors
diagnosed during or after gynecological surgery, as those who had
GI tumors diagnosed ﬁrst had already lived for some time. This
suggests that, when prognostic factors are of concern, a clear
deﬁnition of the reference point e the ﬁrst cancer-related surgery
or gynecological surgery e should be given.
Our ﬁnding that the use of postoperative chemotherapy is
strongly correlated with intraoperative use of chemotherapy, along
with the ﬁnding that the use of the latter is not associated with any
clinical characteristics of the patients, is not very surprising.
Ovarian cancer is by far the most fatal gynecological disease and KT
usually represents a more advanced and aggressive form of ovarian
cancer. As such, the patient’s family is often devastated and grief-
stricken when a patient’s diagnosis is made, and gives up in
many cases. The heavy economic burden to patients and their
families that is associated with chemotherapy, the low per capita
disposable income relative to that in developed countries, and the
lack of a social welfare system in China that can absorb the bulk of
the cost for the treatment of catastrophic diseases such as advanced
ovarian cancer certainly add to the predicament. Even the surgeons
who treat patients are somewhat pessimistic, given the poor
prognosis of KT.
Yet the survival advantage of chemotherapy after ovarian cancer
surgery disappears if survival is considered immediately after the
ﬁrst cancer-related surgery. This may be due to the fact that the
patients who had primary GI tumors diagnosed ﬁrst actually had
longer survival rates (median survival ¼ 18.0 vs. 10.1 months) than
those who were diagnosed synchronously with or after gyneco-
logical surgery. This longer survival rate effectively eliminates any
beneﬁcial effect of chemotherapy if survival is considered after
gynecological surgery. This is actually corroborated by the signiﬁ-
cant difference found in survival between patients who had GI
tumors diagnosed before and after or synchronously with gyne-
cological surgery.
The 5-year survival rate after resection of GI tumors ranges from
20% to 90%, and it decreases precipitously when metastasis, such as
in KT, occurs.18 Our study found that the median survival in 13
patients with a history of previous GI surgery was approximately 9
months. Therefore, treatment for female patients diagnosed with
GI tumors is complicated. Prophylactic oophorectomy in premen-
opausal and postmenopausal women at the time of GI cancer sur-
gery has been the focus of much attention in recent years,6 as theovary is themost commonmetastatic site. Yet it is apparent that the
majority of women with GI cancer would not have KT. This may
explain why no guideline has been made so far concerning pro-
phylactic oophorectomy in these patients.
In summary, our study suggests that optimal cytoreductive
surgery followed by aggressive chemotherapy may improve sur-
vival in gynecological patients with KT. KT patients with unilateral
ovarian mass also seem to have a more favorable prognosis than
those with bilateral masses. Our study also indicates that the
prognostic value of a factor depends on how survival is deﬁned.Acknowledgments
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